



Yearly symposium of the WFN Research Group for ALS/MND

Glasgow, Thursday 6th of December, 08:30 a.m. – 1:00 p.m.

Current and Future Role of Biomarkers in the Diagnosis of ALS

- | | |
|-------------------|--|
| 08:30-09:00 a. m. | Report of the chairman/Elections – Albert Ludolph |
| 09:00-09:30 a. m. | Current state of the development of Blood and CSF-Biomarkers in ALS
– Markus Otto |
| 09:30-10:00 a. m. | State of MRI Biomarkers for ALS – Federica Agosta |
| 10:00-10:30 a. m. | The future role of EMG – Markus Weber |
| 10:30-11:00 a. m. | Break |
| 11:00-11:30 a. m. | Intermediate stage biomarkers – Jeremy Shefner |
| 11:30-12:00 p. m. | Which role could biomarkers play in clinical trials - Merit Cudkowicz |
| 12:00-12:30 p.m. | Should Biomarkers, including EMG, be part of the diagnostic criteria of
ALS? – Ammar Al Chalabi, London |
| 12:30-13:00 p.m. | Panel Discussion – Chair Philip van Damme, Leuven |